Issues in the treatment of Hodgkin's disease

Current Opinion in Oncology

Volumn 10, Issue 5, 1998, Pages 396-402

  Wolf, Jürgen ^a   Engert, Andreas ^a   Diehl, Volker ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; HODGKIN DISEASE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0031789317     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199809000-00005     Document Type: Review

References (26)

1. Tucker MA, Coleman CN, Cox RS, Vargehese A, Rosenberg SA: Risk of second cancer after treatment for Hodgkin's disease. New Engl J Med 1988, 318:76-81.
2. Henry-Amar M: Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's disease. Ann Oncol 1992, 3(suppl. 4):117-128.
3. Bhatia S, Leslie MPH, Robison L, Oberlin O, Greenberg M, Bunin CGG, et al.: Breast cancer and other second neoplasms after childhood Hodgkin's disease. New Engl J Med 1996, 334:745-751.
4. Sankila R, Garwicz S, Olsen JH, Döllner H, Hertz H, Kreuger A, et al.: Risk of subsequent malignant neoplasms among 1641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. J Clin Oncol 1996, 14:1442-1446.
5. Hoppe RT: Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997, 8(suppl 1):115-118. A comprehensive analysis of 2498 long-term surviving patients after treatment of HD in Stanford is given. The risk of death for causes other than Hodgkin's disease, predominantly secondary cancers and cardiac disease, is 17% at 15 years of follow-up (identical to the risk of death from HD) and increases sharply thereafter. These dramatic observations underline the necessity for reduction of toxicity in the treatment of Hodgkin's disease.
6. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG: High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997, 15:1203-1210.
7. Schellong G: The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study Group since 1987. Ann Oncol 1996, 7(suppl. 4):73-78.
8. Van den Berg H, Zsiros J, Behrendt H: Treatment of childhood Hodgkin's disease without radiotherapy. Ann Oncol 1997, 8(suppl. 1):15-17.
9. Löffler M, Diehl V, Pfreundschuh M, Hasenclever D, Nisters-Backes H, Sieber M, et al.: Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 1997, 5:2275-2278.
10. Horning SJ, Hoppe RT, Mason J, Byron WB, Hancock SL, Baer D, Rosenberg SA: Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997, 15:1736-1744.
11. Specht L, Gray RG, Clarke MJ, Peto R, for the International Database on Hodgkin's Disease Overview Study Group: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 1998, 16:830-843. A meta-analysis of more than 3500 patients with early stage HD treated in 21 clinical trials is presented in order to assess the effect of more extensive radiotherapy and of adjuvant combination chemotherapy on treatment outcome. More extensive radiotherapy fields, as well as the addition of chemotherapy to radiotherapy, had no significant effect on long-term survival. This study provides a rationale for further randomized studies focusing on the reduction of toxicity of HD treatment by reduction of radiotherapy fields.
12. Löffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, et al., for the International Database on Hodgkin's Disease Overview Study Group: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998, 16:818-828. Data on 1740 patients with advanced stage Hodgkin's disease treated in 14 clinical trials were analyzed in a meta-analysis focusing on the benefit of radiotherapy in combination with chemotherapy. The results show a significantly inferior long-term survival for combined modality treatment compared with the administration of an appropriate number of cycles of chemotherapy alone. Thus, radiotherapy-related toxicity might be reduced strikingly by reduction of radiotherapy also in advanced stage HD.
13. Connors JM, Klimo P, Adams G, Adams G, Burns BF, Cooper I, et al.: Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997, 15:1638-1645.
14. Rosenberg SA: The management of Hodgkin's disease: half a century of change. Ann Oncol 1996, 7:555-560.
15. Diehl V, Sieber M, Rüffer U, Lathan B, Hasenclever D, Pfreundschuh M, et al., for the German Hodgkin's Lymphoma Study Group: BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997, 8:1-6.
16. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, et al., for the German Hodgkin's Lymphoma Study Group: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced stage Hodgkin's lymphoma. Interim report from a trial of the German Hodgkin's lymphoma study group. J Clin Oncol 1998, in press.
17. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al.: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993, 341:1051-1054.
18. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, et al.: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997, 89:801-813.
19. Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, Goldstone AH: High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Bone Marrow Transplant 1997, 20:745-752.
20. Brice P, Bouabdallah, Moreau P, Divine M, Andre M, Aoudjane M, et al.: Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Bone Marrow Transplant 1997, 20:21-26.
21. Schmitz N, Sextro M, Hasenclever D, Carella A, Fiedler F, Schlimok G, et al.: HD-R1: first results of a randomized trial comparing aggressive chemotherapy with high-dose therapy (HDT) and hematopoietic stem cell transplantation (HSCT) in patients with chemosensitive relapse of Hodgkin's disease (HD) [abstract]. Blood 1997, 10:115a.
22. Majolino I, Pearce R, Taghipour G, Goldstone AH: Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and Non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation registry data. J Clin Oncol 1997, 15:509-517.
23. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, et al.: Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 1996, 87:3418-3428.
24. Jox A, Zander T, Diehl V, Wolf J: Clonal relapse in Hodgkin's disease. New Engl J Med 1997, 337:499.
25. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, et al.: A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997, 89:403-410.
26. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, et al.: Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 1997, 89:2042-2047.